02/18/2026
New FDA labeling changes for menopausal hormone therapy could reshape conversations around menopause treatment.
The agency has eased certain boxed warnings after reviewing newer scientific data, signaling a more nuanced approach to risk communication in women’s health. Safety information remains, but guidance now reflects updated evidence and individualized care considerations.
This shift may influence clinical decisions, patient education, and pharmaceutical market dynamics in the years ahead.
https://www.statsurgicalsupply.com/news/fda-approves-labeling-changes-for-menopausal-hormone-therapy-easing-decades-old-boxed-warnings
On February 12, 2026, the U.S. Food and Drug Administration (FDA) approved significant labeling updates for several menopausal hormone therapy (MHT) products, r...